Immuneering Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMRX research report →
Companyimmuneering.com
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs.
- CEO
- Benjamin J. Zeskind
- IPO
- 2021
- Employees
- 54
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $183.87M
- P/E
- -4.09
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 737.54
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -0.11%
- ROIC
- -0.03%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-56,024,898 · 8.21%
- EPS
- $-1.27 · 37.75%
- Op Income
- $-59,375,969
- FCF YoY
- 17.42%
Performance & Tape
- 52W High
- $10.08
- 52W Low
- $1.40
- 50D MA
- $5.33
- 200D MA
- $5.74
- Beta
- 0.36
- Avg Volume
- 878.97K
Get TickerSpark's AI analysis on IMRX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 13, 26 | Neufeld Leah R | other | 3,628 |
| Feb 3, 26 | Bookman Michael | other | 176,000 |
| Feb 3, 26 | Brakewood Harold Eugene | other | 140,000 |
| Feb 3, 26 | Hall Brett Matthew | other | 344,000 |
| Feb 3, 26 | Matushansky Igor | other | 140,000 |
| Feb 3, 26 | Morales Mallory | other | 140,000 |
| Feb 3, 26 | Neufeld Leah R | other | 140,000 |
| Feb 3, 26 | Zeskind Benjamin J. | other | 688,000 |
| Jan 16, 26 | Brakewood Harold Eugene | buy | 5,250 |
| Jan 15, 26 | Schall Thomas J. | buy | 21,645 |
Our IMRX Coverage
We haven't published any research on IMRX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IMRX Report →